Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Aggressive Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Busulfan; Drug: Clofarabine; Drug: Cyclophosphamide; Drug: Gemcitabine; Drug: Mycophenolate Mofetil; Biological: Rituximab; Drug: Tacrolimus; Drug: Vorinostat Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Burkitt Lymphoma | Cancer & Oncology | Chemotherapy | Lymphoma | Non-Hodgkin's Lymphoma | Prograf | Research | Rituxan | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants